Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

APRIL 22, 2023

When infused back into a mouse model of MS, the backpack-laden monocytes were able to affect MS-specific immune responses, and partially reverse hind limb paralysis and improve motor functions. The results are published in the Proceedings of the National Academy of Sciences (PNAS).

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan. SOURCES: Patrick A.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

Broad Institute

AUGUST 7, 2023

Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways.

Regulations 91

Regulations Clinical Trials Engineering DNA 91

Drug Target Review

JANUARY 15, 2024

To be therapeutically useful, antigenic peptides must be presented in a way that allows immune responses to destroy cancer cells without causing unacceptable damage to healthy tissue. Therefore, therapeutically useful tumour antigens represent a tiny fraction of the genes expressed by a tumour cell.

Engineering 110

Engineering DNA Virus Immune Response 110

PLOS: DNA Science

SEPTEMBER 5, 2024

Researchers from Harvard Medical School describe a new ChatGPT-like model that can guide clinical decision-making to diagnose, treat, and predict survival for several types of cancer. This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer. Their report appears in Nature.

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

Broad Institute

OCTOBER 4, 2023

This is an unprecedented opportunity to evaluate how immune responses work,” said Robert Manguso , who is co-senior author on the study, an associate member at the Broad, and an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School.

Small Molecule 128

Small Molecule Clinical Trials Engineering Trials 128

The Pharma Data

JANUARY 3, 2021

The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), Santa Casa de Misericórdia de Santos Hospital (Santos, Brazil) and INTRIALS, a world-class, full-service Latin American CRO based in São Paulo, Brazil. . NEW YORK and LONDON, Jan. Dr. Howard Weiner (the Robert L.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

NOVEMBER 1, 2020

Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug. Clinical Data Expected by End of Year. NEW YORK and LONDON, Nov.

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52

The Pharma Data

DECEMBER 15, 2020

In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. CUE-300 Series Immuno-STATs may offer autoimmune patients therapeutic benefits without compromising their immune systems.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Broad Institute

NOVEMBER 20, 2024

Isselbacher Professor of Medicine at Harvard Medical School, director of the Center for Computational and Integrative Biology and member of the Department of Molecular Biology at MGH, and co-director of the Center for Microbiome Informatics and Therapeutics at MIT.

Regulations 52

Regulations Immune Response Molecular Biology Disease 52

The Pharma Data

DECEMBER 29, 2020

The vaccine — which right now is known as NVX-CoV2373 — comes in two doses and is designed to enhance the body’s immune response to the coronavirus’ distinctive spike protein. is so sporadic,” Jeremy Luban, a virologist at the University of Massachusetts Medical School, told the Post.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52